

Singapore


December IP lifts 4Q25 GDP and 2025 GDP to 6.5% and 5.0% YoY, respectively

Selena Ling
Chief Economist & Head, OCBC Group Research

- December IP eased to 8.3% YoY (-13.3% MoM sa) from the upwardly revised November print of 18.2% YoY (-7.8% MoM sa), but still beat Bloomberg market consensus forecast of 7.4% YoY and our forecast of 7.2% YoY.
- For full-year 2025, manufacturing grew 8.7% YoY, again the biggest improvement since 2021 (13.3% YoY). By cluster, the outperformers were transport engineering and electronics which expanded 18.7% and 12.7% YoY respectively in 2025. As such, the 4Q25 GDP growth is likely to be revised higher from the advance estimate of 5.7% YoY to 6.5% YoY.
- For now, the AI-related demand momentum still appears resilient and this should lift the manufacturing and export tide for Asian exporting nations including Singapore.

Highlights:

- **December IP eased to 8.3% YoY (-13.3% MoM sa) from the upwardly revised November print of 18.2% YoY (-7.8% MoM sa),** but still beat Bloomberg market consensus forecast of 7.4% YoY and our forecast of 7.2% YoY. This marked the fourth straight month of YoY expansion, but the second consecutive month of MoM sa contraction. Excluding biomedical manufacturing, output still expanded a healthy 16.0% YoY (-4.9% MoM sa). This brought 4Q25 manufacturing growth to 18.8% YoY, up from 5.3% in 3Q25, and marked the biggest surge since 3Q17 (19.3% YoY).
- **For full-year 2025, manufacturing grew 8.7% YoY, again the biggest improvement since 2021 (13.3% YoY).** By cluster, the outperformers were transport engineering and electronics which expanded 18.7% and 12.7% YoY respectively in 2025. The key drivers for both sectors were the MRO jobs from commercial airlines in the aerospace segment as well as work for oil rigs and offshore platforms, while AI-related demand continued to underpin the semiconductor segment. Notably, the semiconductor output expanded 10% YoY in 2025, nearing the 2021 record of 14.5% YoY. In contrast, the biomedical manufacturing cluster shrank 38.8% YoY in December, dragged down by the volatile pharmaceuticals (-69.7% YoY) due to a different mix of active pharmaceutical ingredients.
- **As such, the 4Q25 GDP growth is likely to be revised higher from the advance estimate of 5.7% YoY to 6.5% YoY.** In turn, this would upgrade Singapore's full year GDP growth from the advance estimate of 4.8% YoY to 5.0% YoY. This meant that 2025 saw the strongest GDP growth since 2021 (9.8% YoY), which was on the back of the recovery from the Covid pandemic.
- **For now, the AI-related demand momentum still appears resilient and this should lift the manufacturing and export tide for Asian exporting nations including Singapore.** While we anticipate a moderation in manufacturing momentum to around 3.3% YoY in 1H26 and a further easing to 1.3% YoY in 2H26 due to high base effects in 2H25, there is upside risk to our full-year 2026 GDP growth of around 2% YoY.
- **The external headwinds of geopolitical uncertainties and potential product-specific US tariffs on key sectors like pharmaceuticals and semiconductors remain pertinent,** but the silver lining is that the activity in the transport engineering cluster remains healthy too given the sustained travel demand supporting the MRO pipeline ie the current boost is not purely just electronics. For instance, an estimated 1.52 billion international tourists were recorded globally in 2025, nearly 60 million more than 2024, and marking a new post-pandemic record, whilst visitor spending also hit US\$1.9 trillion (+5% YoY), with international tourism forecast to grow a further 3-4% in 2026, according to the UN Tourism Confidence Index. Some market watchers are also upbeat that as AI moves into edge devices, autonomous systems and smart industrial applications, semiconductor demand should also broaden beyond just data center infrastructure.



Source: EDB, CEIC, OCBC Group Research.

This report is solely for information purposes and general circulation only and may not be published, circulated, reproduced or distributed in whole or in part to any other person without our prior written consent. This report should not be construed as an offer or solicitation for the subscription, purchase or sale of the securities/instruments mentioned herein or to participate in any particular trading or investment strategy. Any forecast on the economy, stock market, bond market and economic trends of the markets provided is not necessarily indicative of the future or likely performance of the securities/instruments. Whilst the information contained herein has been compiled from sources believed to be reliable and we have taken all reasonable care to ensure that the information contained in this report is not untrue or misleading at the time of publication, we cannot guarantee and we make no representation as to its accuracy or completeness, and you should not act on it without first independently verifying its contents. The securities/instruments mentioned in this report may not be suitable for investment by all investors. Any opinion or estimate contained in this report is subject to change without notice. We have not given any consideration to and we have not made any investigation of the investment objectives, financial situation or particular needs of the recipient or any class of persons, and accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of the recipient or any class of persons acting on such information or opinion or estimate. This report may cover a wide range of topics and is not intended to be a comprehensive study or to provide any recommendation or advice on personal investing or financial planning. Accordingly, it should not be relied on or treated as a substitute for specific advice concerning individual situations. Please seek advice from a financial adviser regarding the suitability of any investment product taking into account your specific investment objectives, financial situation or particular needs before you make a commitment to purchase the investment product. In the event that you choose not to seek advice from a financial adviser, you should consider whether the investment product mentioned herein is suitable for you. Oversea-Chinese Banking Corporation Limited ("OCBC Bank"), Bank of Singapore Limited ("BOS"), OCBC Investment Research Private Limited ("OIR"), OCBC Securities Private Limited ("OSPL") and their respective related companies, their respective directors and/or employees (collectively "Related Persons") may or might have in the future, interests in the investment products or the issuers mentioned herein. Such interests include effecting transactions in such investment products, and providing broking, investment banking and other financial or securities related services to such issuers as well as other parties generally. OCBC Bank and its Related Persons may also be related to, and receive fees from, providers of such investment products. There may be conflicts of interest between OCBC Bank, BOS, OIR, OSPL or other members of the OCBC Group and any of the persons or entities mentioned in this report of which OCBC Bank and its analyst(s) are not aware due to OCBC Bank's Chinese Wall arrangement. This report is intended for your sole use and information. By accepting this report, you agree that you shall not share, communicate, distribute, deliver a copy of or otherwise disclose in any way all or any part of this report or any information contained herein (such report, part thereof and information, "Relevant Materials") to any person or entity (including, without limitation, any overseas office, affiliate, parent entity, subsidiary entity or related entity) (any such person or entity, a "Relevant Entity") in breach of any law, rule, regulation, guidance or similar. In particular, you agree not to share, communicate, distribute, deliver or otherwise disclose any Relevant Materials to any Relevant Entity that is subject to the Markets in Financial Instruments Directive (2014/65/EU) ("MiFID") and the EU's Markets in Financial Instruments Regulation (600/2014) ("MiFIR") (together referred to as "MiFID II"), or any part thereof, as implemented in any jurisdiction. No member of the OCBC Group shall be liable or responsible for the compliance by you or any Relevant Entity with any law, rule, regulation, guidance or similar (including, without limitation, MiFID II, as implemented in any jurisdiction).

The information provided herein may contain projections or other forward looking statements regarding future events or future performance of countries, assets, markets or companies. Actual events or results may differ materially. Past performance figures are not necessarily indicative of future or likely performance.

Privileged / confidential information may be contained in this report. If you are not the addressee indicated in the message enclosing the report (or responsible for delivery of the message to such person), you may not copy or deliver the message and/or report to anyone. Opinions, conclusions and other information in this document that do not relate to the official business of OCBC Bank, BOS, OIR, OSPL and their respective connected and associated corporations shall be understood as neither given nor endorsed.

Co.Reg.no.: 193200032W

Disclaimers

This material is being made available to you through an arrangement between Bank of Singapore Limited (Co Reg. No.: 197700866R) (the "Bank") and Oversea-Chinese Banking Corporation Limited ("OCBC Bank") (Co Reg. No.: 193200032W). The Bank and OCBC Bank shall not be responsible or liable for any loss (whether direct, indirect or consequential) that may arise from, or in connection with, any use of or reliance on any information contained in or derived from this material, or any omission from this material, other than where such loss is caused solely by the Bank's or OCBC Bank's wilful default or gross negligence.

Please refer to https://www.bankofsingapore.com/Disclaimers_and_Disclosures.html for cross-border marketing disclaimers and disclosures.